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Abstract. Background: In this study, we aimed at evaluating
the cytotoxic and apoptotic effects of enalapril on human HL60
acute promyelocytic leukaemia cells and at clarifying the roles
of signal transducers and activator of transcription proteins
(STATs) on enalapril-induced cell death. Materials and
Methods: Cell viability and cytotoxicity tests were conducted by
Trypan blue dye exclusion and 2,3-Bis[2-methoxy-4-nitro-5-
sulphophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT)
assays, respectively. Apoptotic analyses were performed by the
AnnexinV-enhanced green fluorescent protein (EGFP) staining
method and by fluorescence microscopy. Expression levels of
STAT3, -5A and -5B genes were analysed by quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR). Results:
The results showed that enalapril reduced viability and
proliferation, and induced apoptosis in HL60 cells in a dose-
and time-dependent manner as compared to untreated controls.
The expression levels of STAT5A gene were significantly
reduced in enalapril-treated HL60 cells as compared to
untreated controls. Conclusion: Taken together, all data showed
for the first time that enalapril has significant anticancer
potential for the treatment of acute premyelocytic leukaemia.
Acute promyelocytic leukaemia (APL), a distinct variant of
acute myelogenous leukaemia (AML), is characterized by
clonal expansion of promyelocytes in the bone marrow and
in the bloodstream resulting from the arrest of the
differentiation of myeloid cells at the promyelocyte phase (1).
In the majority of APL cases, a reciprocal chromosomal
translocation occurs involving the retinoic acid receptor-alpha
(RARα) gene on chromosome 17 and the promyelocytic
leukaemia (PML) gene on chromosome 15 (2). The resultant
PML-RARα fusion protein plays a critical role in the
pathogenesis of APL. Induction therapy for patients with APL
used to be similar to that for AML and included a standard
chemotherapy regimen of anthracycline and, cytarabine
arabinoside (3, 4). Complete remission was sustained
following standard chemotherapy; however, most patients
experienced relapse and long-term disease-free survival was
only 30-40% (5). The introduction of all-trans retinoic acid
(ATRA) (6, 7) has changed the treatment course of APL, and
its combination with anthracycline-based chemotherapy has
become the standard treatment regimen for newly diagnosed
APL patients. Following a combination therapy, the complete
response rates were found to be more than 90% and cure rates
were approximately 80% (8-10). Arsenic trioxide (ATO) in
treatment of APL relapse has also given excellent results (11).
Haematopoietic cell proliferation and differentiation is
regulated by cytokines that are also known as interferons,
interleukins and colony-stimulating factors. Upon the
binding of the cytokine with the cell surface receptor that is
lacking intrinsic tyrosine kinase ability, the signalling
cascade is induced and associated Janus kinases (JAKs) are
activated by cross-phosphorylation. Activated JAKs first
phosphorylate the receptor itself and then the signal
transducers and activator of transcription proteins (STATs)
(12). STATs are latent cytoplasmic transcription factors that
upon activation function as signal transducers and
transcription factors. Seven mammalian STAT proteins have
been discovered: STAT1 to -4, and STAT5A, STAT5B, and
STAT6 (13). They are known to be involved in several
cellular processes, such as cell growth, cell differentiation,
apoptosis and immune responses. Therefore, dysregulation
of STATs, either due to constitutive activation or functional
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impairment, can lead to cellular transformation (14, 15).
STAT1, -3 and -5 are known to be involved in the
development or suppression of malignant transformation.
STAT1 mediates growth-inhibitory signals and induces
apoptosis, and therefore has a tumour-suppressive role in
oncogenesis. It also contributes to the host rejection of
tumours (16, 17). Inhibition of the STAT3 pathway has been
shown to induce apoptosis in cancerous cells (18, 19).
STAT5A and -5B proteins have also been shown to be
necessary for the development of malignancy (17). 
The renin-angiotensin system (RAS) or the renin-
angiotensin-aldosterone system (RAAS) is a hormone
system that systemically regulates cardiovascular
homoeostasis. However, several studies have shown that
local RAS may mediate cellular processes, such as
proliferation, tissue angiogenesis, apoptosis and
inflammation (20). Components of the RAS were shown to
be expressed in several adult tissues (21). The presence of a
local bone marrow RAS, affecting physiological and
pathological haematopoiesis was first hypothesized in 1996
by Haznedaroglu and co-workers. Almost all of the major
components of RAS were demonstrated in haematopoietic
stem cells (HSC), progenitors and bone marrow
microenvironment (22-24). It is the paracrine action of
locally expressed RAS, instead of its circulating counterpart,
that appears vital for tumourigenesis. Expression of
components of the RAS such as renin, angiotensin (Ang),
angiotensin I-II receptor (AT1R, AT2R) and antigen-
converting enzyme (ACE) were identified in various types
of carcinoma, including brain, lung, breast, prostate, colon,
and skin (20). The RAS is also a vital element in the process
of development of neoplastic haematopoiesis (25). The
presence of ACE surface antigen (CD143) within leukemic
bone marrow (26), on the K562 erythroleukaemia cell line
(27) and ACE-expressing macrophages in lymph nodes in
Hodgkin’s disease (28) has already been shown. In addition,
CD143 has been observed to be over expressed in leukaemic
blast cells, and it has been found that ACE is directly
correlated to the bone marrow blast count (29). Renin
activity has also been described in leukemic blasts (30, 31).
ACE inhibitors have been widely used in clinical studies
for the treatment of hypertension, heart failure, coronary
artery disease and diabetes mellitus. Recently, studies
examining the anti-tumoural effects of ACE inhibitors have
gained significance (32). Enalapril is a carboxyl-group ACE
inhibitor used for the treatment of high blood pressure that
works by regulating the RAAS.
Many chemotherapeutic agents have been used in the
treatment of acute leukaemia yet, to date, there is no
definitive treatment. In this study, we aimed to evaluate the
cytotoxic and apoptotic effects of the ACE inhibitor enalapril
on human HL60 acute promyelocytic leukaemia cells and to
clarify the mechanisms of enalapril-induced cell death. 
Materials and Methods
Cell line, culture conditions and chemicals. Human HL60 acute
promyelocytic leukaemia cells were kindly provided by Dr Serdar
Bedii Omay from Ege University. HL60 cells were maintained in
RPMI-1640 medium containing 10% foetal bovine serum (FBS) and
1% penicillin–streptomycin at 37˚C in 5% CO2. Enalapril was
obtained from Sigma Chemical (St. Louis, MO, USA). Enalapril (50
mg) was dissolved in 1 ml RPMI-1640 medium and stock solutions
were prepared. Trypan blue dye was obtained from Sigma Chemical.
2,3-Bis[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-
carboxanilide inner salt (XTT) Cell Proliferation Assay was obtained
from Biological Industries (Israel). AnnexinV-EGFP Apoptosis
Detection Kit was obtained from Biovision (CA, USA). All the other
chemicals and tissue culture supplies were obtained from Sigma
Chemical unless otherwise specified.
Measurement of cell viability and cytotoxicity. In order to measure
the cytotoxic effect of enalapril on HL60 cells, 2×105 cells were
seeded into 24-well plates containing 1 ml growth medium in the
absence or presence of increasing concentrations of enalapril (1 nM,
10 nM, 100 nM, 5 μM and 10 μM), and incubated at 37˚C in 5%
CO2. Cell viability was assessed at 0, 24, 48, 72 and 96 h post-
incubation by Trypan blue dye exclusion assay as indicated in the
manufacturer’s instructions.
The concentration of enalapril that inhibited cell growth by 50%
(IC50) was determined by XTT assay. Briefly, 2×104 HL60 cells
were plated into 96-well plates containing 100 μl of the growth
medium in the absence or presence of increasing concentrations of
enalapril (1 nM, 10 nM, 100 nM, 5 μM and 10 μM) and incubated
at 37˚C in 5% CO2. After 24, 48, 72 and 96 h incubation, cells were
treated with 50 μl XTT solution for 4 hours and the absorbance was
recorded at 492 nm using an ELISA reader and the IC50 dose of
enalapril was calculated from the cell proliferation plots (33). 
Evaluation of apoptosis. Apoptosis induced by enalapril in HL60 cells
was detected by fluorescence microscopy using AnnexinV-EGFP
Apoptosis Detection Kit (Biovision) as described in the manufacturer’s
instructions. Briefly, HL60 cells were treated with 7 μM of enalapril
and apoptosis was induced. At 0, 24, 48, 72 and 96 h time points, 1-
5×105 cells were collected and 500 μl 1× binding buffer was added to
the cell suspension. Subsequently, 5 μl annexinV-EGFP and 5 μl
propidium iodide (PI) were added, and the cells were incubated in the
dark for 5 min at room temperature. Consequently, the cells were
transferred onto a coverglass and morphologically examined by
fluorescence microscopy.
Total RNA isolation and quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR). Total RNA was isolated from HL60 cells
treated with 7 μM (IC50 value) of enalapril at 24, 48, 72 and 96 h post-
incubation using Trizol reagent (including guanidium thiocyanate,
phenol and sodium citrate) as described by the manufacturer. One
microgramme of total RNA was reverse transcribed using FirstStrand
cDNA Synthesis Kit (Life Sciences GE Healthcare, Piscataway, NJ,
USA) in accordance with the instructions provided by the
manufacturer. After 1 h incubation at 37˚C, the reaction was stopped at
65˚C for 10 min. The resulting total cDNAs were then used to
determine the mRNA levels of STAT3, STAT5A, and STAT5B. Q-PCR
was performed with gene-specific primers and probes using the Fast
Start DNA Master Hybridisation Probes (Roche Applied Science,
Penzberg, Upper Bavaria, Germany) and Glucose-6-phosphate
dehydrogenase (G6PDH) House Keeping Gene Kit (Roche Applied
Science). The G6PDH gene was used as an internal positive control
in all PCR reactions, and its amplification product provided both a
control for PCR performance and a reference for quantification of PCR
products. The primer sequences were (TibMolBiol, Berlin, Germany):
STAT3 forward: 5’-ACCAACAATCCCAAGAATGT-3’, reverse: 5’-
CGATGCTCAGTCCTCGC-3’; STAT5A forward: 5’GAAGCTGAA
CGTGCACATGAATC-3’, reverse: 5’-GTAGGGACAGAGTCTTCA
CCTGG-3’; STAT5B forward: 5’-AGTTTGATTCTCAGGAAAGAA
TGT-3’, reverse: 5’-TCCATCAACAGCTTTAG CAGT-3’. Two
microlitres of the reverse transcriptase reaction was amplified using
these primers for 50 cycles (95˚C, 10 s; 56˚C, 10 s; 72˚C, 5 s). The
mRNA levels of STAT3, -5A, and -5B were determined in a Real-Time
LightCycler Instrument (Roche Applied Science). The relative
expression level for each gene was calculated by dividing the mRNA
copy number of the target gene by the G6PDH mRNA copy number.
qRT-PCR experiments were performed at least in three independent
trials. Statistical significance was analysed by using ANOVA (analysis
of variance) and p<0.05 was considered significant.
Results
Enalapril reduced viability and proliferation of HL60 cells in
a time- and dose-dependent manner. In order to detect the
potential cytotoxic effects of enalapril on human HL60 cells,
we used both Trypan blue dye exclusion and XTT cell
proliferation assays. The results of the Trypan blue dye
exclusion assay showed that there was a dose- and time-
dependent reduction in cell viability as compared to untreated
controls (Figure 1). Viability of untreated HL60 cells
remained constant for the initial 72 hours, before declining in
number due to over-confluence in the spent medium. Viability
of HL60 cells treated with increasing concentrations of
enalapril (3-10 μM) was observed to drop steadily over the
experiment. The IC50 value of enalapril was calculated from
cell survival plots and was determined to be 7 μM (Figure 1).
The degree of cytotoxicity induced by enalapril was
assessed by XTT assay. Enalapril reduced cell proliferation
significantly in a time- and dose-dependent manner (Figure 2). 
Enalapril induced early and late apoptosis in HL60 cells.
Apoptotic cells were morphologically examined under
fluorescence microscopy, and cellular changes were identified.
Apoptotic cells were stained green, whereas necrotic cells
were stained with PI and observed in red. Cells shown as both
green and red were defined to be in late apoptosis (Figure 3A)
and live cells were observed in blue (Figure 3B). Following
the evaluation of apoptosis in HL60 cells treated with 7 μM
enalapril, an increase was observed in the number of early
apoptotic cells at 48 hours and the rate was found to be 20%
(Figure 4). However, this value was statistically insignificant
when compared to that of untreated controls, (p>0.05) and the
difference between enalapril-treated and untreated control
groups disappeared after 72 hours. At later time points, early
apoptotic HL60 cells were not observed; only HL60 cells in
late apoptosis were present (Figure 4). 
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Figure 1. Effects of enalapril on the viability of HL60 cells. Trypan blue dye exclusion assays were performed using duplicate samples in at least
two independent experiments. The error bars represent the standard deviations, and when not seen, they are smaller than the thickness of the lines
on the graphs. Statistical significance was determined using two-way analysis of variance, and p<0.05 was considered significant. Control: untreated
control cells.
Differential expression patterns of STAT3, STAT5A, and
STAT5B in enalapril-treated HL60 cells. Expression levels
of STAT3, -5A and -5B genes were examined in HL60
leukaemia cells treated with 7 μM of enalapril, by qRT-PCR.
The results revealed that the expression of STAT3 decreased
in enalapril-treated HL60 cells within the first 24 hours and
the difference was of borderline statistical significance when
compared to untreated controls (p<0.065). However, the
change in the expression of the STAT3 gene for the total
duration of the experiment was statistically insignificant as
compared to the control group (p>0.05) (Figure 5A). At 24,
48 and 72 hours post-incubation, the expression of the
STAT5A gene was significantly reduced in enalapril-treated
HL60 cells when compared to untreated controls (p<0.05)
(Figure 5B). The changes in the expression levels of the
STAT5B gene were found to be statistically insignificant in
enalapril-treated HL60 cells when compared to the negative
control group (p>0.05) (Figure 5C). 
Discussion
Many chemotherapeutic agents have been used for the
treatment of acute leukaemia, but no definitive treatment has
yet been described. Therefore, study of novel treatment
regimens, including patient-based, in vitro and in vivo, are
underway. For the first time, with this study, we evaluated
the potential cytotoxic effect of enalapril, an ACE inhibitor
generally used for treatment of high blood pressure, on
human HL60 acute PML cells.
It is well known that haematopoiesis is regulated by
several factors including growth factors, cytokines, cell
surface receptors and the microenvironmental signals in the
bone marrow. Since haematopoietic bone marrow is an area
of excessive cell growth, the presence of a local, intrinsic
RAS within the bone marrow was suggested (34). As ACE
and other angiotensin peptides have a role in cellular
processes, such as cell proliferation and migration, but also
in angiogenesis (35-37), the involvement of RAS in the
development of malignant haematopoiesis has gained
significance (22, 25, 38). Recent data showed the existence
of ACE in human primitive lympho-haematopoietic cells,
and embryonic, foetal and adult haematopoietic tissues (39,
40). ACE inhibitors are widely used as anti-hypertensive
medicines but lately they have gained significance as
anticancer agents (32). Their antitumoural effects were first
described in a study by Lever et al. (41) in which breast and
lung cancer incidence decreased in patients receiving ACE
inhibitors, including enalapril. 
In the first stage of our study, we examined the potential
cytotoxic and apoptotic effects of enalapril on HL60 cells,
and investigated the possible mechanisms involved in cell
death. The results of Trypan blue cell viability and XTT cell
ANTICANCER RESEARCH 32: 2885-2894 (2012)
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Figure 2. Percentage changes in cytotoxicity of enalapril. The concentration of enalapril that inhibited cell growth by 50% (IC50) was calculated from
cytotoxicity plots. The XTT assays were performed using duplicate samples in at least two independent experiments. The error bars represent the
standard deviations, and when not seen, they are smaller than the thickness of the lines on the graphs. Statistical significance was determined using
two-way analysis of variance, and p<0.05 was considered significant. Control: untreated control cells.
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Figure 3. Morphological examination of apoptosis in HL-60 cells treated with 7 μM of enalapril. AnnexinV-EGFP and PI staining method was used
and cells were visualized by using fluorescence microscopy. The nuclei of cells that have lost membrane integrity are stained red (PI) and their
plasma membranes are stained green (EGFP) (A). Cells that are stained both red and green are determined to be necrotic whereas green cells are
apoptotic. Viable cells are shown in blue (B).
proliferation assays revealed that enalapril reduced viability
and proliferation of HL60 cells in a dose- and time-
dependent manner. Previously, the potential antiproliferative
effect of captopril, another ACE inhibitor, was observed on
primitive haematopoietic stem and progenitor cells in vitro
(42), however, it was shown to have no effect on
proliferation of myeloid leukaemia cells (43). Similarly to
our results, in a recent study, the growth and colony-forming
ability of AML cells was shown to decrease in vitro in a
dose-dependent manner following incubation with an ACE
inhibitor (44). In a different study, ACE inhibitors captopril
and trandolapril, and losartan, which is an angiotensin II
receptor antagonist, were shown to inhibit cell proliferation
and induce apoptosis in K562 chronic myeloid leukaemia
cells which seemed to be related to Ang II-induced small
mothers against decapentaplegic (SMAD) activation (45). 
Measurement of plasma membrane phosphatidylserine
externalization, using fluorescently labelled annexin V, is
widely used for the detection of apoptotic cells and is
advantageous as it offers the possibility of detecting early
phases of apoptosis before the loss of cell membrane
integrity (46). In order to see if enalapril induces apoptosis
in HL60 acute leukaemia cells, we incubated HL60 cells
with a 7 μM dose of enalapril and applied the AnnexinV-
EGFP staining method at certain time points. Apoptotic cells
were morphologically examined by fluorescence microscopy
and the results showed that necrotic cells were in abundance
when compared to apoptotic cells. The results showed that
there was a slight increase in the number of early apoptotic
cells in enalapril-treated HL60 cells within the early stages
of experiment, however, this difference was not permanent
and remained statistically insignificant when compared to
untreated controls until the end of the experiment. 
STAT proteins play an important role in cellular processes.
Dysregulation of the STAT pathway may lead to formation of
malignant cells (15). It is already known that the JAK-STAT
pathway is a vital element in the interaction between the
components of RAS present in the bone marrow and
haematopoiesis (47). In the second stage of our study, we
aimed to identify the pathway(s) that play a role in the
cytotoxicity of enalapril towards HL60 cells. Therefore, we
investigated the expression levels of STAT3, STAT5A and
STAT5B genes in enalapril-treated HL60 cells by qRT-PCR.
The results showed that the change in expression levels of
STAT3 and STAT5B were statistically insignificant (p>0.05) in
enalapril-treated HL60 cells when compared to untreated
controls, whereas the expression of STAT5A significantly
decreased in a time-dependent manner in enalapril-treated
HL60 cells when compared to the control group (p<0.05).
These results suggest that STAT5A might have a significant
role in enalapril-induced leukaemia cell death. Previously,
enalapril was shown to inhibit Ang II-induced proliferation of
rat cardiac fibroblasts in vitro by blocking the phosphorylation
of STAT3 (48). In a recent study, retinal expressions of
STAT3/5 were investigated in chemically induced diabetes in
rats, in enalapril-treated and untreated control groups.
Following the RT-PCR, STAT3 and STAT5 expression was
found to be absent in the enalapril-treated group (49). 
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Figure 4. Percentage changes in early and late apoptosis of HL-60 cells treated with 7 μM of enalapril, as determined by AnnexinV-EGFP method.
Statistical significance was determined using the Student’s t-test, and p<0.05 was considered significant. ENA: enalapril treated cells; Control:
untreated control cells.
In conclusion, our study has shown for the first time that
enalapril has cytotoxic and apoptotic effects on HL60 acute
promyelocytic leukaemia cells and STAT5A may have
significant roles in enalapril-induced cell death.
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